Daicel (JP:4202)
:4202
Want to see JP:4202 full AI Analyst Report?
Top Page
Daicel
(4202)
Select Model
Select Model
Rating:55Neutral
Price Target:
¥1,169.00
▼(-6.29% Downside)
Action:Reiterated
Date:05/13/26
The score is held back primarily by weakening profitability and inconsistent free cash flow, plus bearish technical trend signals (price below key moving averages and negative MACD). A strong dividend yield provides partial support, but the negative P/E highlights stressed earnings and tempers the valuation uplift.
Positive Factors
Diversified B2B product mix
Daicel's portfolio spans safety-system components, engineering plastics and specialty chemicals sold into multiple industrial end markets. This diversification reduces single-market exposure, supports stable order flows from OEM/tier supply chains, and underpins durable demand across cycles.
Negative Factors
Profitability deterioration
A marked decline in net income and operating margins erodes internal funding capacity and raises dependence on external financing. Sustained margin weakness reduces returns on invested capital, weakens cushioning against raw-material or energy cost spikes, and impairs long-term earnings visibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified B2B product mix
Daicel's portfolio spans safety-system components, engineering plastics and specialty chemicals sold into multiple industrial end markets. This diversification reduces single-market exposure, supports stable order flows from OEM/tier supply chains, and underpins durable demand across cycles.
Read all positive factors
Daicel (4202) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥304.37B
Dividend Yield4.27%
Average Volume (3M)536.76K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue Growth-1.18%
EPS Growth-78.57%
CountryJP
Employees11,134
SectorBasic Materials
Sector Strength58
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)155.50
Shares Outstanding266,942,700
10 Day Avg. Volume480,400
30 Day Avg. Volume536,760
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)0.91
Price to Sales (P/S)0.56
P/FCF Ratio128.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,440.00Price Target Upside15.43% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)160.82
Revenue Forecast (FY)¥597.84B
Daicel Business Overview & Revenue Model
Company Description
Daicel Corporation manufactures and sells cellulosic derivatives, organic chemicals, plastics, pyrotechnic devices, and other products in Japan, Asia, North America, and Europe. It operates through Medical/Healthcare, Smart, Safety, Materials, Eng...
How the Company Makes Money
Daicel makes money primarily by manufacturing and selling chemical and materials products (largely B2B) and related components, with revenue recognized through product shipments under supply contracts and purchase orders. Key revenue streams inclu...
Daicel Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
58
Neutral
Cash Flow
52
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 578.81B | 579.63B | 586.53B | 558.06B | 538.03B | 467.94B |
| Gross Profit | 153.46B | 146.29B | 165.84B | 160.39B | 147.04B | 139.68B |
| EBITDA | 92.89B | 85.41B | 102.38B | 96.10B | 79.08B | 78.89B |
| Net Income | 41.14B | 10.18B | 49.48B | 55.84B | 40.68B | 31.25B |
Balance Sheet | ||||||
| Total Assets | 884.09B | 833.93B | 813.83B | 839.17B | 765.61B | 698.84B |
| Cash, Cash Equivalents and Short-Term Investments | 75.85B | 68.81B | 65.14B | 73.18B | 93.84B | 90.53B |
| Total Debt | 317.90B | 304.25B | 286.12B | 304.12B | 321.97B | 283.55B |
| Total Liabilities | 483.88B | 463.55B | 438.79B | 464.30B | 455.17B | 419.29B |
| Stockholders Equity | 384.69B | 355.60B | 359.99B | 358.90B | 295.21B | 272.02B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 2.51B | 23.44B | 11.11B | -20.54B | -501.00M |
| Operating Cash Flow | 0.00 | 67.84B | 93.41B | 76.73B | 26.85B | 42.99B |
| Investing Cash Flow | 0.00 | -49.26B | -47.87B | -55.37B | -36.89B | -46.53B |
| Financing Cash Flow | 0.00 | -21.26B | -48.85B | -52.37B | 12.76B | -5.45B |
Daicel Technical Analysis
Negative
1247.50
Price Trends
1273.30
Negative
1366.54
Negative
1327.77
Negative
Market Momentum
-32.48
Positive
39.03
Neutral
34.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4202, the sentiment is Negative. The current price of 1247.5 is above the 20-day moving average (MA) of 1214.00, below the 50-day MA of 1273.30, and below the 200-day MA of 1327.77, indicating a bearish trend. The MACD of -32.48 indicates Positive momentum. The RSI at 39.03 is Neutral, neither overbought nor oversold. The STOCH value of 34.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4202.
Daicel Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ¥531.20B | 15.11 | 6.52% | 1.82% | 4.95% | 52.94% | |
73 Outperform | ¥320.47B | 9.57 | 5.47% | 3.41% | 0.55% | 25.37% | |
73 Outperform | ¥413.93B | 9.42 | 9.59% | 3.91% | -2.06% | 46.42% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
58 Neutral | ¥234.32B | 9.89 | 1.47% | 4.29% | -5.02% | ― | |
58 Neutral | ¥896.25B | -17.36 | -2.50% | 3.49% | -4.57% | -190.44% | |
55 Neutral | ¥304.37B | -3.18 | 9.34% | 4.27% | -1.18% | -78.57% |
* Basic Materials Sector Average
JP:4202
Daicel
1,167.00
21.89
1.91%
JP:4118
Kaneka
5,233.00
1,618.31
44.77%
JP:4182
Mitsubishi Gas Chemical Company
4,613.00
2,569.57
125.75%
JP:4208
UBE Industries
2,890.50
752.50
35.20%
JP:4205
Zeon
2,058.00
692.64
50.73%
JP:4203
Sumitomo Bakelite Co., Ltd.
6,310.00
2,780.55
78.78%
Daicel Corporate Events
Daicel Introduces Performance-Based Stock Plan for Directors to Align Pay with Long-Term Goals
May 12, 2026
Daicel Corporation has approved the introduction of a performance-based stock compensation plan for its internal directors, aiming to align their interests more closely with shareholders and to incentivize sustainable growth in corporate value. Th...
Daicel to Cancel 4.05% of Outstanding Shares to Tighten Capital Base
May 12, 2026
Daicel Corporation’s board has approved the cancellation of 10,800,000 shares of its common stock, representing 4.05% of shares outstanding prior to the move. Following the cancellation, scheduled for May 21, 2026, the company’s total ...
Daicel Profit Plunges on Materials Weakness and Plant Impairment
May 12, 2026
Daicel reported a 1.2% decline in net sales to 579.6 billion yen for the year ended March 2026, with operating income falling 31% to 42.1 billion yen and EBITDA down 16.6%. Profit attributable to owners of the parent plunged 79.4% to 10.2 billion ...
Daicel Profit Slumps but Dividend Held as Company Signals Modest Recovery in FY2027
May 12, 2026
Daicel Corporation reported a 1.2% decline in consolidated net sales to ¥579.6 billion for the year ended March 31, 2026, with operating profit down 31% to ¥42.1 billion and profit attributable to owners of the parent plunging 79.4% to &...
Daicel Books Large Guarantee Provision as It Receives Major Dividend from Subsidiaries
May 11, 2026
Daicel Corporation has received a dividend of 10.95 billion yen from its consolidated subsidiary Daicel (China) Investment Co., Ltd., which was resolved in late January and paid in February, and this income has been recognized as non-operating inc...
Daicel Completes ¥13.8 Billion Share Buyback Program
Apr 2, 2026
Daicel Corporation has completed a share repurchase program authorized by its board, acquiring a total of 10,094,500 shares of its common stock for approximately 13.75 billion yen. The purchases were conducted on the Tokyo Stock Exchange between N...
Daicel Books ¥32 Billion Impairment and Slashes FY2026 Profit Forecast
Mar 26, 2026
Daicel will book an extraordinary impairment loss of about ¥32 billion in the fourth quarter of the fiscal year ending March 2026, after concluding that a new cyclic olefin copolymer resin plant under construction will be less profitable due ...
Daicel Advances Share Buyback, Repurchasing Over 8.5 Million Shares
Mar 3, 2026
Daicel has continued its share repurchase program, acquiring 700,200 shares of its common stock for about ¥1.14 billion on the Tokyo Stock Exchange between February 1 and February 28, 2026. This move is part of a previously approved buyback f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.